Dyax Revenue Growth Rates (DYAX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Dyax Corp  (DYAX)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

DYAX's Revenue Growth by Quarter and Year

Dyax's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DYAX Revenue (in millions $) FY 2015 FY 2014 FY 2013 FY 2012
4th Quarter December -
3rd Quarter September 24.73
2nd Quarter June 26.37
1st Quarter March 20.42
FY 71.52





DYAX Revenue third quarter 2015 Y/Y Growth Comment
Dyax Corp reported Revenue increase of 12.46% year on year in the third quarter 2015, to $ 24.73 millions, this is lower than Dyax Corp's recent average Revenue improvement of 29.64%.

Looking into third quarter 2015 results within Medical Laboratories industry 13 other companies have achieved higher Revenue growth. While Dyax Corp' s Revenue growth of 12.46% ranks overall at the positon no. 1257 in the third quarter 2015.


DYAX Revenue ( Y/Y Growth %) 2015
 2014 2013 2012
4th Quarter December - 54.39 % 5.18 % 88.15 %
3rd Quarter September 12.46 % 60.63 % 4.5 % 29.32 %
2nd Quarter June 34.61 % 72.75 % -19.17 % -35.88 %
1st Quarter March 44.62 % 17.28 % 4.79 % 39.95 %
FY   - 51.55 % -1.32 % -

Financial Statements
Dyax's third quarter 2015 Revenue $ 24.73 millions DYAX's Income Statement
Dyax's third quarter 2014 Revenue $ 21.99 millions Quarterly DYAX's Income Statement


DYAX Revenue (Quarter on Quarter Growth %)

 2015
 2014 2013 2012
4th Quarter December - 18.37 % 23.16 % 22.37 %
3rd Quarter September -6.22 % 12.25 % 20.72 % -6.63 %
2nd Quarter June 29.14 % 38.74 % -5.81 % 22.11 %
1st Quarter March -21.55 % -16.25 % -24.89 % 34.86 %
FY (Year on Year)   - 51.55 % -1.32 % -


Back to DYAX Growth rate Comparisons >> Back to DYAX Growth rate Comparisons >>


Revenue third quarter 2015 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #14
Healthcare Sector #220
Overall #1257

Revenue Y/Y Growth Statistics
High Average Low
88.23 % 29.64 % -35.86 %
(Jun 30 2014)   (Jun 30 2013)
Revenue third quarter 2015 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #14
Healthcare Sector #220
Overall #1257
Revenue Y/Y Growth Statistics
High Average Low
88.23 % 29.64 % -35.86 %
(Jun 30 2014)   (Jun 30 2013)

Revenue by Quarter for the Fiscal Years 2012, 2013, 2014, 2015

Dyax's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
38.73 % 11.18 % -21.55 %
(Jun 30 2014)  


DYAX's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2015 Dyax Corp disclosed decline in Revenue from the second quarter by -6.22% to $ 24.73 millions, from $ 26.37 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2015 Revenue, this plainly could not be substantial to rescue 's company achievement, Most analysts pointed out.

Within Medical Laboratories industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Dyax's Revenue growth quarter on quarter, overall rank is 3183.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #35
Healthcare Sector #368
Overall #3183
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #35
Healthcare Sector #368
Overall #3183
Revenue Q/Q Growth Statistics
High Average Low
38.73 % 11.18 % -21.55 %
(Jun 30 2014)  


DYAX's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2015 Dyax Corp disclosed decline in Revenue from the second quarter by -6.22% to $ 24.73 millions, from $ 26.37 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2015 Revenue, this plainly could not be substantial to rescue 's company achievement, Most analysts pointed out.

Within Medical Laboratories industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Dyax's Revenue growth quarter on quarter, overall rank is 3183.


Dyax's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2015)		 12 Months Ending
(Jun 30 2015)		 12 Months Ending
(Mar 31 2015)		 12 Months Ending
(Dec 31 2014)		 12 Months Ending
(Sep 30 2014)
Cumulative Revenue 12 Months Ending $ 97.55 $ 94.81 $ 88.02 $ 81.72 $ 72.55
Y / Y Revenue Growth (TTM) 34.45 % 47.56 % 57.18 % 51.55 % 36.64 %
Year on Year Revenue Growth Overall Ranking # 585 # 627 # 0 # 0 # 1706
Seqeuential Revenue Change (TTM) 2.89 % 7.71 % 7.71 % 12.64 % 12.92 %
Seq. Revenue Growth (TTM) Overall Ranking # 1010 # 1405 # 0 # 0 # 1634


Cumulative Revenue growth Comment
Assuming the Dyax's fiscal year would have ended in Sep 30 2015, Dyax would have reprted above average annual Revenue rise of 34.45% year on year, of $ 98 millions.
This marks a slow-down of the companys growth trends and from the 47.56% increase in Jun 30 2015.

In the Healthcare sector 112 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 585, from total ranking in previous quarter at 627.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 7
Healthcare Sector # 113
Overall # 585

Revenue TTM Y/Y Growth Statistics
High Average Low
60.21 %
 30.37 %
0.53 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 7
Sector # 169
S&P 500 # 1010
Cumulative Revenue growth Comment
Assuming the Dyax's fiscal year would have ended in Sep 30 2015, Dyax would have reprted above average annual Revenue rise of 34.45% year on year, of $ 98 millions.
This marks a slow-down of the companys growth trends and from the 47.56% increase in Jun 30 2015.

In the Healthcare sector 112 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 585, from total ranking in previous quarter at 627.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 7
Healthcare Sector # 113
Overall # 585

Revenue TTM Y/Y Growth Statistics
High Average Low
60.21 %
30.37 %
0.53 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 7
Sector # 169
S&P 500 # 1010




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
DYAX's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2015 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2015
Wearable Health Solutions, Inc.21.38%$ 21.380 millions
Tenet Healthcare Corp21.15%$ 21.153 millions
Perspective Therapeutics Inc 21.04%$ 21.036 millions
Statera Biopharma Inc fka Cytocom Inc 20.82%$ 20.820 millions
Abeona Therapeutics Inc 20.76%$ 20.763 millions
Alexion Pharmaceuticals Inc 20.08%$ 20.083 millions
Trivascular Technologies, Inc.20.02%$ 20.018 millions
Portola Pharmaceuticals inc 19.98%$ 19.984 millions
Hill rom Holdings Inc 19.61%$ 19.612 millions
Pacira Biosciences inc 19.53%$ 19.530 millions
Cba Florida Inc 19.48%$ 19.481 millions
Acceleron Pharma inc18.44%$ 18.444 millions
Abbvie Inc 18.43%$ 18.430 millions
Ligand Pharmaceuticals Incorporated18.22%$ 18.219 millions
Biomarin Pharmaceutical Inc18.13%$ 18.127 millions
Atricure Inc 17.79%$ 17.786 millions
Celgene Corp17.75%$ 17.753 millions
Capforce Inc 17.49%$ 17.488 millions
Syneos Health Inc 17.25%$ 17.253 millions
Vericel Corporation17.09%$ 17.095 millions
United Therapeutics Corporation17.05%$ 17.054 millions
Globus Medical Inc 16.30%$ 16.305 millions
Tandem Diabetes Care Inc 16.30%$ 16.297 millions
Htg Molecular Diagnostics Inc16.18%$ 16.175 millions
Curis Inc 15.87%$ 15.871 millions
Conformis inc 15.76%$ 15.764 millions
Misonix Inc 15.68%$ 15.677 millions
Cytosorbents Corporation15.60%$ 15.596 millions
Pediatrix Medical Group Inc 15.29%$ 15.286 millions
Apyx Medical Corp15.25%$ 15.247 millions


About Dyax Revenue Growth Rates (DYAX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.